SER icon

Serina Therapeutics

5.67 USD
+0.03
0.53%
At close May 16, 4:00 PM EDT
After hours
6.09
+0.42
7.41%
1 day
0.53%
5 days
-6.28%
1 month
8.00%
3 months
16.91%
6 months
13.40%
Year to date
11.18%
1 year
-29.39%
5 years
-80.06%
10 years
-94.05%
 

About: Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The Company has one reportable segment relating to the research and development of its POZ platform.

Employees: 13

0
Funds holding %
of 7,457 funds
Analysts bullish %

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

19% more capital invested

Capital invested by funds: $1.6M [Q4 2024] → $1.9M (+$305K) [Q1 2025]

0% more funds holding

Funds holding: 25 [Q4 2024] → 25 (+0) [Q1 2025]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q4 2024] → 1 (+0) [Q1 2025]

0% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 3

0.21% less ownership

Funds ownership: 3.59% [Q4 2024] → 3.38% (-0.21%) [Q1 2025]

17% less repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 6

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target
$11
94%
upside
Avg. target
$11
94%
upside
High target
$11
94%
upside

1 analyst rating

positive
100%
neutral
0%
negative
0%
Jones Trading
Justin Walsh
11% 1-year accuracy
1 / 9 met price target
94%upside
$11
Buy
Initiated
11 Mar 2025

Financial journalist opinion

Based on 3 articles about SER published over the past 30 days

Neutral
GlobeNewsWire
3 days ago
Serina Therapeutics Makes Grants to New Employees Under Inducement Plan
HUNTSVILLE, AL, May 14, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company advancing its lead IND candidate SER-252 for advanced Parkinson's disease, enabled by its proprietary POZ Platform™ drug optimization technology, announced that it has made grants of options to purchase an aggregate of 15,000 shares of Serina's common stock to two new non-executive employees on March 20, 2025 (each, an “Option Grant”). Each Option Grant has an exercise price equal to the closing price of Serina's common stock on March 20, 2025. The Option Grants were offered as material inducement to the employees' employment. The Option Grants were approved by the Compensation Committee of Serina's Board of Directors on March 20, 2025, pursuant to Serina's 2024 Inducement Equity Plan to align their interests with Serina's stockholders and to promote the success of Serina's business. The Option Grants were made in reliance on the employment inducement exemption under the NYSE American's Company Guide Section 711(a) which requires public disclosure of inducement awards. Serina is issuing this press release pursuant to Section 711(a) of NYSE American's Company Guide. The Option Grants shall vest and become exercisable with respect to one-fourth of the aggregate number of shares subject to each Option Grant on the first anniversary of the grant date, and the remaining three-fourths of the aggregate number of shares subject to each Option Grant shall vest in a series of three substantially equal annual installments thereafter, such that the Option Grant will be vested as of the third anniversary of the grant date, subject to continued employment with Serina.
Serina Therapeutics Makes Grants to New Employees Under Inducement Plan
Neutral
GlobeNewsWire
1 week ago
Serina Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights
HUNTSVILLE, May 08, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today reported its financial results for the first quarter ended March 31, 2025, along with recent business highlights.
Serina Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights
Neutral
GlobeNewsWire
2 weeks ago
Serina Therapeutics to Present at JonesResearch Virtual CNS Day
HUNTSVILLE, AL, April 29, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, announced that Steve Ledger, Chief Executive Officer, will present at the JonesResearch Hosts: Virtual CNS Day on April 29, 2025, at 12:00 p.m. EDT.
Serina Therapeutics to Present at JonesResearch Virtual CNS Day
Neutral
GlobeNewsWire
1 month ago
Serina Therapeutics to Present at the 4th LNP Formulation & Process Development Summit
HUNTSVILLE, AL, April 15, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, announced that Randall Moreadith, M.D., Ph.D., Chief Development Officer, will present new data at the 4th LNP Formulation & Process Development Summit 2025 in Boston, MA. The presentation, titled "The PEG Dilemma – A Solution," will take place on Tuesday, April 15, at 9:30 AM ET. The session will focus on addressing challenges related to anti-PEG antibodies in mRNA vaccines and therapeutics and introduces Serina's POZ-lipid technology as an immune-silent alternative to PEG-lipids.
Serina Therapeutics to Present at the 4th LNP Formulation & Process Development Summit
Neutral
GlobeNewsWire
1 month ago
Serina Therapeutics Secures $5 Million in Funding to Support Advancement of SER-252 into Clinical Development in Advanced Parkinson's Disease
HUNTSVILLE, Ala., April 08, 2025 (GLOBE NEWSWIRE) -- S erina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today announced the closing of a $5 million financing from strategic shareholders. Proceeds from the transaction will support the continued development of SER-252 (POZ-apomorphine), Serina's lead clinical candidate for Advanced Parkinson's disease, as the company prepares to initiate a Phase 1 clinical trial in the fourth quarter of 2025.
Serina Therapeutics Secures $5 Million in Funding to Support Advancement of SER-252 into Clinical Development in Advanced Parkinson's Disease
Neutral
GlobeNewsWire
1 month ago
Serina Therapeutics to Present at the Jones Healthcare and Technology Innovation Conference
HUNTSVILLE, AL, April 07, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, announced that Steve Ledger, Chief Executive Officer, will present at the Jones Healthcare and Technology Innovation Conference in Las Vegas, NV on April 9, 2025, at 3:00 p.m. PDT.
Serina Therapeutics to Present at the Jones Healthcare and Technology Innovation Conference
Neutral
GlobeNewsWire
1 month ago
Serina Therapeutics Reports Full Year 2024 Financial Results and Recent Business Highlights
HUNTSVILLE, March 24, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today reported its financial results for the full year ended December 31, 2024 and provided recent business highlights.
Serina Therapeutics Reports Full Year 2024 Financial Results and Recent Business Highlights
Neutral
GlobeNewsWire
1 month ago
Serina Therapeutics to Present at the American Chemistry Society (ACS) Spring 2025 Meeting
HUNTSVILLE, AL, March 24, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug delivery technology, announced that Randall Moreadith, M.D., Ph.D., Chief Development Officer, will present new data at the ACS Spring 2025 Meeting and Expo in San Diego, CA. His presentation, titled "A Non-Immunogenic LNP for Gene Delivery: Characterization of Poly(oxazoline) Lipid Nanoparticles," will highlight findings on the immunogenic profile of Serina's proprietary POZ-lipid technology.
Serina Therapeutics to Present at the American Chemistry Society (ACS) Spring 2025 Meeting
Neutral
GlobeNewsWire
3 months ago
Serina Therapeutics Appoints Dr. Jay Venkatesan to its Board of Directors
HUNTSVILLE, AL, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today announced the appointment of Jay Venkatesan, MD, MBA, to its Board of Directors. Dr. Venkatesan brings deep expertise in biotechnology investment, company building, and strategic growth, having successfully led and advised multiple biopharma companies through pivotal stages of development, including high-profile mergers and acquisitions.
Serina Therapeutics Appoints Dr. Jay Venkatesan to its Board of Directors
Neutral
GlobeNewsWire
3 months ago
Serina Therapeutics Receives Second $5 Million Tranche to Strengthen Cash Position Ahead of Phase 1 Clinical Trial in Advanced Parkinson's Disease Patients
HUNTSVILLE, Feb. 03, 2025 (GLOBE NEWSWIRE) -- S erina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company, today announced the successful closing of the second $5 million tranche of its previously announced $10 million equity financing with strategic shareholder JuvVentures (UK) Limited. The transaction provides Serina with funding to continue advancing SER-252 (POZ-apomorphine), enabled by its proprietary POZ Platform™ drug optimization technology, into a Phase 1 clinical trial in advanced Parkinson's disease patients in the second half of 2025. The closing represented the second tranche of the $10 million total financing announced on December 2, 2024.
Serina Therapeutics Receives Second $5 Million Tranche to Strengthen Cash Position Ahead of Phase 1 Clinical Trial in Advanced Parkinson's Disease Patients
Charts implemented using Lightweight Charts™